[Blasch-kolinear psoriasis revealed by infliximab therapy]
M Sfia1, B Roth-Mall, M-C Tortel
1Service de dermatologie, hôpital Pasteur, 39, avenue de la Liberté, 68024 Colmar cedex, France. sadokmehdi@yahoo.fr
Annales De Dermatologie Et De Venereologie
|December 17, 2009
Summary
Blaschko-linear psoriasis, a rare condition, was identified in a patient during treatment with infliximab. This biologic therapy revealed persistent linear lesions despite clearing diffuse psoriasis, suggesting distinct cell population responses.
Area of Science:
- Dermatology
- Immunology
- Genetics
Background:
- Blaschko-linear psoriasis is a rare dermatosis with diagnostic challenges.
- Few publications exist on this specific psoriasis subtype.
- Differential diagnosis from other inflammatory Blaschko-linear dermatoses is complex.
Observation:
- A 29-year-old male patient with chronic, therapy-resistant psoriasis was treated with infliximab.
- After four infusions, diffuse psoriatic plaques resolved almost completely.
- Persistent Blaschko-linear lesions remained on the left arm and leg despite ongoing treatment.
Findings:
- Infliximab treatment revealed Blaschko-linear lesions in a patient with psoriasis.
- The linear lesions persisted despite the resolution of generalized psoriatic plaques.
- This suggests differential responses to biologic therapy within the patient's cell populations.
Implications:
- The case highlights a unique presentation of Blaschko-linear psoriasis.
- It suggests the presence of distinct cell populations with varying responses to infliximab.
- This finding may influence future diagnostic and therapeutic strategies for complex psoriasis cases.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...